|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Wander, SA, Cohen, O, Gong, X, Johnson, GN, Buendia-Buendia, JE, Lloyd, MR, Kim, D, Luo, F, Mao, P, Helvie, K, Kowalski, KJ, Nayar, U, Waks, AG, Parsons, SH, Martinez, R, Litchfield, LM, Ye, XS, Yu, C, Jansen, VM, Stille, JR, Smith, PS, Oakley, GJoseph, Chu, QS, Batist, G, Hughes, ME, Kremer, JD, Garraway, LA, Winer, EP, Tolaney, SM, Lin, NU, Buchanan, SG, Wagle, N|
|Date Published||2020 May 13|
Mechanisms driving resistance to CDK4/6 inhibitors in HR+ breast cancer have not been clearly defined. Whole exome sequencing of 59 tumors with CDK4/6i exposure revealed multiple candidate resistance mechanisms including RB1 loss, activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2, and loss of ER expression. In vitro experiments confirmed that these alterations conferred CDK4/6i resistance. Cancer cells cultured to resistance with CDK4/6i also acquired RB1, KRAS, AURKA, or CCNE2 alterations, which conferred sensitivity to AURKA, ERK, or CHEK1 inhibition. Three of these activating alterations-in AKT1, RAS, and AURKA-have not to our knowledge been previously demonstrated as mechanisms of resistance to CDK4/6 inhibitors in breast cancer preclinically or in patient samples. Together, these eight mechanisms were present in 66% of resistant tumors profiled and may define therapeutic opportunities in patients.
|Alternate Journal||Cancer Discov|